Charcot-Marie-Tooth Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Findings obtained in the present study, broadening the spectrum of clinical manifestations of disorders associated with HSP27 mutations, support the hypothesis of a continuum between CMT2 and dHMN forms and suggest a possible common spectrum between these entities and several forms of CMT plus pyramidal features (HMSN V), providing important implications for molecular genetic testing.
|
20660910 |
2010 |
Charcot-Marie-Tooth Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified a novel stop loss variant in NEFH that is likely pathogenic for CMT2, and the results provide further evidence for the role of an aberrant assembly of neurofilament in CMT.
|
29587262 |
2018 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SH3TC2, PMP2, and BSCL2 genes are related to autosomal recessive (AR) Charcot-Marie-Tooth (CMT) disease type 1, autosomal dominant (AD)-CMT1, and AD-CMT2, respectively.
|
29336362 |
2018 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ganglioside-induced differentiation-associated protein 1 gene (GDAP1) cause Charcot-Marie-Tooth type 2 (CMT2), a severe autosomal recessive form of neuropathy associated with axonal phenotypes.
|
19381883 |
2009 |
Charcot-Marie-Tooth Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Charcot-Marie-Tooth neuropathy type 2 (CMT2) is characterized by normal or mildly reduced nerve conduction velocity with decreased amplitude and axonal loss without hypertrophic features.
|
10716658 |
1999 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the HSPB1 and HSPB8 genes in a large clinically well-characterized series of dHMN and CMT type 2 (CMT2) cases and families using linkage analysis and direct sequencing of these genes.
|
18832141 |
2008 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Less frequently, axonal CMT (CMT2) associated with MPZ mutations has been described.
|
17940173 |
2007 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two major types can be distinguished based on electrophysiologic phenotypes: CMT type 1 (CMT1) displays uniformly decreased nerve conduction velocity associated with a demyelinating hypertrophic neuropathy, and CMT type 2 (CMT2) displays normal or near-normal nerve conduction velocity associated with a neuronal defect.
|
8128981 |
1993 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Charcot-Marie-Tooth disease (CMT) is a heterogeneous disorder and is traditionally classified into two major types, CMT type 1 (CMT1) and CMT type 2 (CMT2).
|
12402337 |
2002 |
Charcot-Marie-Tooth Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, we identified histone deacetylase 6 (HDAC6), which deacetylates α-tubulin, as a potential therapeutic target in axonal CMT (CMT2).
|
27957719 |
2017 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Twelve CMT patients who did not have decreased nerve conduction velocities consistent with a diagnosis of CMT type 2 (CMT2) were found not to have the CMT1A duplication.
|
8105684 |
1993 |
Charcot-Marie-Tooth Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Charcot-Marie-Tooth (CMT) disease represents a clinically and genetically heterogeneous group of inherited neuropathies caused by aberration of the intimate relationship between the myelin sheath and the axon; disorders causing demyelination are classified as CMT1 and those causing axonal loss as CMT2.
|
11898586 |
2002 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The neuronal form of this disorder is referred to as Charcot-Marie-Tooth type II disease (CMT2).
|
7573046 |
1995 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently a set of mutations in the neurofilament light gene (NF-L) was reported in patients suffering from axonal and demyelinating forms of Charcot-Marie-Tooth disease (CMT1 and CMT2).
|
15535039 |
2004 |
Charcot-Marie-Tooth Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Electrophysiologically, at least two types of CMT can be distinguished; CMT1 which has decreased nerve conduction velocities (NCV) and CMT2 which has normal or near normal NCV with decreased amplitudes.
|
1341967 |
1992 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study therefore provides evidence for genetic heterogeneity between the hypertrophic and the neuronal forms of Charcot-Marie-Tooth disease and demonstrates that the CMT2 gene is not allelic to either of the CMT1 genes mapped to date.
|
1733853 |
1992 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Point mutations in the coding region of the myelin genes, peripheral myelin protein 22 (PMP22), myelin protein zero (MPZ) or connexin 32 (Cx32) have been reported in CMT patients, including CMT type 1 (CMT1), CMT type 2 (CMT2) and Déjérine-Sottas neuropathy (DS) patients, and only in the coding region of PMP22 in HNPP families lacking a deletion.
|
9187667 |
1997 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three loci are known for the autosomal dominant forms of axonal CMT (CMT2), but none have yet been identified for autosomal recessive axonal CMT (ARCMT2).
|
10441578 |
1999 |
Charcot-Marie-Tooth Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The point prevalence (January 1, 2007) for all CMT subtypes in Iceland was 12.0/10(5), 10.1/10(5) for CMT1 and 2.0/10(5) for CMT2.
|
19893324 |
2010 |
Charcot-Marie-Tooth Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Charcot-Marie-Tooth disease (CMT) represents a group of neurodegenerative disorders typically characterised by demyelination (CMT1) or distal axon degeneration (CMT2) of motor and sensory neurons.
|
23840650 |
2013 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The other CMT families with dominant inheritance but without duplication included one family with CMT1B (demyelinating CMT mapped on chromosome 1) (1.6%), 14 families with CMT2 axonal neuropathy (22.2%), and 10 families with X-linked dominant CMT (15.9%).
|
8413376 |
1993 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in dynamin 2 (DNM2) have been associated with autosomal dominant centronuclear myopathy, dominant intermediate Charcot-Marie-Tooth (CMT) type B and CMT2.
|
18394888 |
2008 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Electroneuromyography revealed an axonal motor and sensory neuropathy in 3 different families, very evocative of type II Charcot-Marie-Tooth (CMT2) disease, although none had mutations in the known CMT2 genes.
|
24804794 |
2014 |
Charcot-Marie-Tooth Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Charcot-Marie-Tooth (CMT) disease is genetically heterogeneous and subdivided into demyelinating (CMT 1) and axonal (CMT 2) types based on neurophysiology findings.
|
19809938 |
2009 |
Charcot-Marie-Tooth Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Charcot-Marie-Tooth disease (CMT) has been classified into two types, CMT1 and CMT2, demyelinating and axonal forms, respectively.
|
15549395 |
2005 |